#USA #Austin #Genprex #Reqorsa #TUSC2

Genprex Presents New Data on Reqorsa® Gene Therapy

Genprex, Inc. has recently announced significant findings regarding its lead gene therapy candidate, Reqorsa® (quaratusugene ozeplasmid), as presented during the 2026 Annual Scientific Meeting held by the Gerontological Society of America. This clinical-stage biotechnology company, listed on NASDAQ as GNPX, aims to restore essential biological functions disrupted by diseases like cancer and diabetes through innovative gene therapies.

Overview of Findings

The latest research suggests that Reqorsa® promotes an increase in TUSC2 expression, a vital tumor suppressor gene linked to enhanced cellular maintenance and resilience, particularly related to the aging process. TUSC2 levels tend to decline with age, impacting various tissues including the brain. Studies using mice showed that the absence of TUSC2 led to several premature aging symptoms such as loss of sensory abilities and reduced lifespan.

In the study, researchers focused on analyzing whole-blood transcriptome data from 11 lung cancer patients who underwent treatment with Reqorsa®. The analysis aimed to understand the transcriptional shifts induced by the therapy over different intervals following its administration. The data revealed that at five hours post-treatment, the response was largely characterized by immune responses, while the 24-hour mark reflected a shift toward cellular maintenance pathways, including key processes like autophagy, mitochondrial adaptation, and protein quality control.

Implications for Aging and Health

These findings may have profound implications, highlighting Reqorsa’s potential not only in treating lung cancer but also in addressing aging-associated stress. Ryan Confer, the President and CEO of Genprex, emphasized that this research extends the therapeutic potential of Reqorsa®. It suggests that TUSC2 plays a significant role in controlling certain aspects of human aging while also providing insights into the biological mechanisms activated by the therapy.

Mark Berger, Genprex’s Chief Medical Officer, further elaborated on the observed biphasic response. Initially, a robust immune response characterizes the five-hour window, characteristic of a reaction to the lipid-based delivery system of the therapy. However, as time progressed, the focus shifted towards mechanisms that support cell health and preservation, diminishing earlier inflammatory responses. Notably, this study indicates a suppression of growth signaling pathways while mitochondrial gene expression showed an intriguing pattern of transient suppression followed by recovery.

Future Studies and Applications

This research aligns with ongoing studies at Genprex exploring the broader applications of Reqorsa®, including its effects on cancer immune responses via enhancement of Natural Killer (NK) cell activity. By analyzing the relationship between mitochondrial metabolism and molecular aging, the company aims to delve deeper into the connections between cancer pathology and aging dynamics, potentially paving the way for innovative treatment options.

The implications of this research resonate with the growing interest in therapies targeting the intersection of cancer treatment and age-related health issues. With regulatory fast-track designations already granted by the FDA for its lung cancer programs, Genprex is well-positioned to continue advancing its clinical trials for lung cancer therapies while exploring Reqorsa’s applications in diabetes through different gene therapy initiatives.

In summary, Genprex's findings unveil promising avenues for utilizing Reqorsa® in enhancing cellular strength against aging-related stress while battling cancer, marking a significant milestone in gene therapy developments. This dual action holds potential, bridging cancer treatment with longevity science, paving the way for novel therapeutic strategies that address both disease management and age-related health concerns.

For more details, interested parties can access the full data and research insights through Genprex’s official platforms.